Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tisotumab vedotin - Genmab/Seagen

Next Previous
Drug Profile

Tisotumab vedotin - Genmab/Seagen

Alternative Names: HuMax-TF; HuMax-TF-ADC; Humax®-TF-ADC; TF-011-MMAE; Tisotumab vedotin-tftv - Genmab/Seagen; TIVDAK

Latest Information Update: 05 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer Genmab; Seagen; ZAI Lab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 01 Sep 2025 Registered for Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in Hong Kong (IV)
  • 07 Aug 2025 Launched for Cervical cancer (Second-line therapy or greater, Recurrent, Late-stage disease, Metastatic disease) in Japan (IV) before August 2025
  • 01 Apr 2025 Registered for Cervical cancer (Second-line therapy or greater, Recurrent, Metastatic disease, Monotherapy) in European Union (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top